NodThera_logo.jpg
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech
August 05, 2024 10:16 ET | NodThera
NodThera Named a ‘Fierce 15’ Company by Fierce Biotech Philadelphia, PA, August 5, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic...
NodThera_logo.jpg
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
June 12, 2024 07:00 ET | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
NodThera_logo.jpg
NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors
February 19, 2024 07:00 ET | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors ...
NodThera_logo.jpg
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
February 05, 2024 07:00 ET | NodThera
Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...
NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor
July 11, 2023 07:00 ET | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor NT-0796 demonstrates...
NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors
June 20, 2023 07:00 ET | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors Oral, small molecule, clinical candidates NT-0249...